The 2027 benefit decision needs a shared value view before cardiometabolic care is judged as a point solution.
Population health leaders need a credible account of member access and engagement, while finance needs evidence it can stand behind.
Who you’d be doing this for
“My CFO wants the numbers next week, and I still can’t tell whether employees never saw the benefit or chose not to use it.”
Kofi Fadahunsi · Population Health Manager
Owns cardiometabolic benefit performance for a self-insured employer and prepares the recommendation for its 2027 vendor review.
What is at stake
Employers are questioning whether low enrollment reflects limited access or limited demand as 2027 benefit decisions approach. You must weigh a clear executive decision path against claims, outcome, and ROI evidence that matures at different speeds.
Why it isn’t already fixed
Every obvious fix costs something else. That’s the part you’d have to decide.
- member access vs financial attribution
- speed to 2027 decisions vs evidence maturity
- standardised programme vs employer-specific permissions
- clinical credibility vs simple executive narratives
Why Sword Health
Pulse connects cardiometabolic engagement, outcomes, claims, billing, and ROI evidence across employer benefit decisions.
Written with these in mind
Not your kind of problem? 30 more at Sword Health, or browse every organization.
This is the setup. The work is inside.
Running it puts you in the room: the full situation and its constraints, stakeholders who push back in their own words, and the decisions that are yours to make. What you produce becomes a Day One Plan — work you can show someone instead of describing.